About Hikal Pharmaceuticals Limited
Data last updated: 23 July 2025
Hikal Pharmaceuticals Limited was a private limited company based in Navi Mumbai, Maharashtra, India. The company has been amalgamated - it was merged with another entity and no longer exists as a separate legal entity. It specialised in mineral products, a part of the broader metals and mining sector. Incorporated on 23 September 1985.
Registered with ROC Mumbai under CIN U26921MH1985PTC171427.
Capital: an authorised share capital of ₹20 Lakh and a paid-up capital of ₹20 Lakh. It was led by directors including Shivakumar Kheny and Ravindra Murgendra Khadabadi.
Last AGM: 21 August 2008. Financial statements filed for year ended 31 March 2008. Office: Great Eastern Chambers Sector 11 Cbd Belapur, Navi Mumbai, Maharashtra, India – 400614.
The company was associated with 1 brand - Hikal.
The company has been merged (amalgamated) with another entity and no longer exists separately. Business activities, if any, continue under the successor entity. The last known website on record is hikal.com.
-
Email**************
-
Telephone**************
-
Website**************
-
Social Media
-
Registered AddressGreat Eastern Chambers Sector 11 Cbd Belapur, Navi Mumbai, Maharashtra, India – 400614
-
IndustryMetal & Minerals, Mineral Products, Manufacturing
- Historical Financials and ratios
- Shareholding pattern and group structure
- Charges with holder and property details
- Litigation, compliance and MCA filings
- PDF report delivered after checkout
CIN History of Hikal Pharmaceuticals Limited
Hikal Pharmaceuticals Limited has one previous CIN (Corporate Identification Number): U26921KA1985PTC007167. The current CIN is U26921MH1985PTC171427, which is the unique identifier assigned by the Registrar of Companies.
| CIN | Status |
|---|---|
| U26921MH1985PTC171427 | Current |
| U26921KA1985PTC007167 | Previous |
Associated Brands with Hikal Pharmaceuticals Limited
Hikal Pharmaceuticals Limited operates one associated brand: Hikal. These brands represent Hikal Pharmaceuticals Limited's diversified market presence and brand portfolio.
Competitors & Alternatives of Hikal Pharmaceuticals Limited
Brands and companies operating in the same space as Hikal Pharmaceuticals Limited include Laurus Labs, Symbiotec, Beijing Biostar Technologies and 5 more.
| Competitor | Description | Location | Founded |
|---|---|---|---|
Laurus Labs
|
Pharmaceutical and biotechnology company | Hyderabad, India, India | 2005 |
Symbiotec
|
Non-sterile steroid hormone-based APIs and intermediates are manufactured. | Indore, India, India | 2002 |
Beijing Biostar Technologies
|
APIs, intermediates, and biochemical reagents are developed and manufactured. | Beijing, China, China | 2002 |
Sterling Pharma Solutions
|
Contract development, manufacturing, and analytical services for APIs are offered. | Dudley, United Kingdom, United Kingdom | 2016 |
Provepharm Life Solutions
|
APIs and drug products are developed and valorized in pharmaceuticals. | Marseille, France, France | 1998 |
Snapdragon Chemistry
|
Drug discovery and development service provider | Cambridge, United States, United States | 2014 |
SeQuent
|
APIs are developed and manufactured for therapeutic areas. | Bengaluru, India, India | 2002 |
Jubilant Pharma
|
Pharmaceuticals, APIs, and radiopharmaceuticals are manufactured by the company. | Noida, India, India | 1978 |
Auditor Details of Hikal Pharmaceuticals Limited
Hikal Pharmaceuticals Limited is audited by SRBC & CO. LLP (ICAI peer reviewed, certificate valid till 2029-02-28) for the financial year 2026, as reported in its NSE exchange filings. The statutory auditor is responsible for expressing an independent opinion on whether the financial statements present a true and fair view in accordance with applicable accounting standards.
| Name | Financial year | Audit opinion |
|---|---|---|
| SRBC & CO. LLP (ICAI peer reviewed, certificate valid till 2029-02-28) | FY 2026 | Declaration of unmodified opinion |
Board of Directors of Hikal Pharmaceuticals Limited
Hikal Pharmaceuticals Limited is currently managed by 3 directors, with 1 former director having served the organization. The current Directors play a crucial role in shaping the company's strategic direction and governance.
| Name | Designation | Appointment Date | Tenure | Status |
|---|---|---|---|---|
|
Shivakumar Kheny
Also directs:
Keen Mustard Ventures Llp, Keen Mustard M G Road Llp, Keen Mustard Serious Slice Llp and 3 more
|
Director | 10 Jul 2004 | 21 Years 11 Months | As last reported |
| Ravindra Murgendra Khadabadi | Director | 22 Dec 2005 | 20 Years 6 Months | As last reported |
|
Sham Vinayak Wahalekar
Also directs:
Acoris Research Limited
|
Director | 18 Jun 2004 | 22 Years 0 Months | As last reported |
Financials of Hikal Pharmaceuticals Limited FY 2026 filings available
Hikal Pharmaceuticals Limited reported revenue of ₹1,712.6 Cr (down 7.91% YoY) for FY 2026. Profit growth despite declining revenue indicates effective cost management and margin discipline.
| Metrics | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Revenue from Operations | ₹1,712.6 Cr | ₹1,859.8 Cr | ₹1,784.6 Cr | ₹2,023.03 Cr | ₹1,720.44 Cr | ₹1,507.26 Cr |
| Other Income | ₹12.3 Cr | ₹5 Cr | ₹2.45 Cr | ₹5.41 Cr | ₹4.98 Cr | ₹3.7 Cr |
| Total Income | ₹1,724.9 Cr | ₹1,864.8 Cr | ₹1,787.05 Cr | ₹2,028.44 Cr | ₹1,725.42 Cr | ₹1,510.96 Cr |
| Cost of Materials Consumed | ₹798.6 Cr | ₹882.6 Cr | ₹805.15 Cr | ₹1,121.59 Cr | ₹906.71 Cr | ₹781.9 Cr |
| Purchases of Stock-in-Trade | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 |
| Changes in Inventories | -₹36.9 Cr | -₹45.3 Cr | ₹19.51 Cr | -₹14.56 Cr | ₹1.67 Cr | -₹5.58 Cr |
| Employee Benefit Expense | ₹270.3 Cr | ₹247.1 Cr | ₹246.53 Cr | ₹222.44 Cr | ₹164.32 Cr | ₹156.57 Cr |
| Finance Costs | ₹62.1 Cr | ₹75.2 Cr | ₹56.37 Cr | ₹48.1 Cr | ₹36.2 Cr | ₹52.42 Cr |
| Depreciation & Amortisation | ₹163.8 Cr | ₹134.4 Cr | ₹117.61 Cr | ₹109.01 Cr | ₹85.24 Cr | ₹82.46 Cr |
| Other Expenses | ₹460.2 Cr | ₹447 Cr | ₹446.38 Cr | ₹436.49 Cr | ₹324.85 Cr | ₹301.22 Cr |
| Total Expenses | ₹1,718.1 Cr | ₹1,741 Cr | ₹1,691.55 Cr | ₹1,923.07 Cr | ₹1,518.99 Cr | ₹1,368.99 Cr |
| Profit Before Exceptional Items & Tax | ₹6.8 Cr | ₹123.8 Cr | ₹95.5 Cr | ₹105.37 Cr | ₹206.43 Cr | ₹141.97 Cr |
| Exceptional Items | -₹85.1 Cr | ₹0 | ₹0 | ₹0 | ₹0 | -₹15.4 Cr |
| Profit Before Tax | -₹78.3 Cr | ₹123.8 Cr | ₹95.5 Cr | ₹105.37 Cr | ₹206.43 Cr | ₹126.57 Cr |
| Total Tax Expense | -₹29.5 Cr | ₹33 Cr | ₹25.9 Cr | ₹26.98 Cr | ₹73.28 Cr | ₹42.14 Cr |
| Net Profit | -₹48.8 Cr | ₹90.8 Cr | ₹69.6 Cr | ₹78.39 Cr | ₹133.15 Cr | ₹84.43 Cr |
| attributable to Owners | - | ₹0 | ₹0 | - | ₹0 | - |
| attributable to NCI | - | ₹0 | ₹0 | - | ₹0 | - |
| Other Comprehensive Income | -₹2.4 Cr | -₹1.4 Cr | -₹61 Lakh | -₹56 Lakh | -₹1.44 Cr | -₹13 Lakh |
| Total Comprehensive Income | -₹51.2 Cr | ₹89.4 Cr | ₹68.99 Cr | ₹77.83 Cr | ₹131.71 Cr | ₹84.3 Cr |
| EBITDA (computed) | ₹232.7 Cr | ₹333.4 Cr | ₹269.48 Cr | ₹262.48 Cr | ₹327.87 Cr | ₹276.85 Cr |
| Basic EPS | ₹-3.96 | ₹7.36 | ₹5.64 | ₹6.36 | ₹10.80 | ₹6.85 |
| Diluted EPS | ₹-3.96 | ₹7.36 | ₹5.64 | ₹6.36 | ₹10.80 | ₹6.85 |
| Metrics | FY 2026 | FY 2025 | FY 2024 | FY 2023 |
|---|---|---|---|---|
| Total Assets | ₹2,365.4 Cr | ₹2,528.9 Cr | ₹2,487.14 Cr | ₹2,385.47 Cr |
| Non-current Assets | ₹1,481.3 Cr | ₹1,533.5 Cr | ₹1,520.53 Cr | ₹1,446.46 Cr |
| Current Assets | ₹884.1 Cr | ₹995.4 Cr | ₹966.61 Cr | ₹939.01 Cr |
| Property, Plant & Equipment | ₹1,327.1 Cr | ₹1,356.7 Cr | ₹1,060.48 Cr | ₹948.19 Cr |
| Inventories | ₹358.1 Cr | ₹334.5 Cr | ₹303.72 Cr | ₹316.74 Cr |
| Trade Receivables | ₹441.6 Cr | ₹522.4 Cr | ₹550.34 Cr | ₹441.78 Cr |
| Cash & Equivalents | ₹9.6 Cr | ₹13 Cr | ₹12.7 Cr | ₹26.73 Cr |
| Equity (Net Worth) | ₹1,198.8 Cr | ₹1,262.3 Cr | ₹1,187.66 Cr | ₹1,133.47 Cr |
| Equity Share Capital | ₹24.7 Cr | ₹24.7 Cr | ₹24.66 Cr | ₹24.66 Cr |
| Borrowings (Non-current) | ₹373.1 Cr | ₹367.2 Cr | ₹422.85 Cr | ₹489.88 Cr |
| Borrowings (Current) | ₹308 Cr | ₹395.1 Cr | ₹391.89 Cr | ₹258.08 Cr |
| Total Debt (computed) | ₹681.1 Cr | ₹762.3 Cr | ₹814.74 Cr | ₹747.96 Cr |
| Current Liabilities | ₹678.9 Cr | ₹789.5 Cr | ₹756.63 Cr | ₹661.55 Cr |
| Total Liabilities | ₹1,166.6 Cr | ₹1,266.6 Cr | ₹1,299.48 Cr | ₹1,252 Cr |
| Metrics | FY 2026 | FY 2025 | FY 2024 | FY 2023 |
|---|---|---|---|---|
| Operating Cash Flow | ₹302 Cr | ₹280.4 Cr | ₹186.72 Cr | ₹315.31 Cr |
| Investing Cash Flow | -₹145.3 Cr | -₹136.5 Cr | -₹173.75 Cr | -₹292.33 Cr |
| Financing Cash Flow | -₹160.1 Cr | -₹143.6 Cr | -₹27 Cr | -₹7.69 Cr |
| Capital Expenditure | ₹148.1 Cr | ₹137.3 Cr | ₹204.19 Cr | ₹302.62 Cr |
| Free Cash Flow (computed) | ₹153.9 Cr | ₹143.1 Cr | -₹17.47 Cr | ₹12.69 Cr |
| Dividends Paid | ₹12.3 Cr | ₹14.8 Cr | ₹14.83 Cr | ₹12.34 Cr |
| Net Change in Cash | -₹3.4 Cr | ₹30 Lakh | -₹14.03 Cr | ₹15.29 Cr |
| Metrics | Q4 FY26 | Q3 FY26 | Q2 FY26 | Q1 FY26 | Q4 FY25 | Q3 FY25 | Q2 FY25 | Q1 FY25 | Q4 FY24 | Q3 FY24 | Q2 FY24 | Q1 FY24 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue from Operations | ₹519.4 Cr | ₹494.3 Cr | ₹318.5 Cr | ₹380.4 Cr | ₹552.4 Cr | ₹447.7 Cr | ₹452.9 Cr | ₹406.8 Cr | ₹514.1 Cr | ₹447.57 Cr | ₹434.88 Cr | ₹388.05 Cr |
| Other Income | ₹6.6 Cr | ₹2.8 Cr | ₹1.9 Cr | ₹1 Cr | ₹50 Lakh | ₹3.6 Cr | ₹40 Lakh | ₹50 Lakh | ₹46 Lakh | ₹6 Lakh | ₹99 Lakh | ₹94 Lakh |
| Total Income | ₹526 Cr | ₹497.1 Cr | ₹320.4 Cr | ₹381.4 Cr | ₹552.9 Cr | ₹451.3 Cr | ₹453.3 Cr | ₹407.3 Cr | ₹514.56 Cr | ₹447.63 Cr | ₹435.87 Cr | ₹388.99 Cr |
| Cost of Materials Consumed | ₹210.3 Cr | ₹187.6 Cr | ₹218.7 Cr | ₹182 Cr | ₹210.7 Cr | ₹212.8 Cr | ₹224.3 Cr | ₹234.8 Cr | ₹183.17 Cr | ₹192.61 Cr | ₹212.3 Cr | ₹217.07 Cr |
| Purchases of Stock-in-Trade | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 |
| Changes in Inventories | ₹6.3 Cr | ₹44.4 Cr | -₹92.4 Cr | ₹4.8 Cr | ₹21.5 Cr | -₹1.9 Cr | -₹22.4 Cr | -₹42.5 Cr | ₹51.08 Cr | ₹14.21 Cr | ₹82 Lakh | -₹46.6 Cr |
| Employee Benefit Expense | ₹67.2 Cr | ₹70.6 Cr | ₹69.6 Cr | ₹62.9 Cr | ₹63.4 Cr | ₹64.5 Cr | ₹62.1 Cr | ₹57.1 Cr | ₹63.78 Cr | ₹61.31 Cr | ₹61.81 Cr | ₹59.63 Cr |
| Finance Costs | ₹14.6 Cr | ₹15.5 Cr | ₹14.9 Cr | ₹17.1 Cr | ₹17.9 Cr | ₹18.7 Cr | ₹18.8 Cr | ₹19.8 Cr | ₹15.26 Cr | ₹14.24 Cr | ₹13.08 Cr | ₹13.79 Cr |
| Depreciation & Amortisation | ₹42 Cr | ₹41.2 Cr | ₹41.2 Cr | ₹39.4 Cr | ₹37.7 Cr | ₹33.2 Cr | ₹31.7 Cr | ₹31.8 Cr | ₹32.34 Cr | ₹28.97 Cr | ₹28.57 Cr | ₹27.73 Cr |
| Other Expenses | ₹130.2 Cr | ₹109 Cr | ₹115.4 Cr | ₹105.6 Cr | ₹133.4 Cr | ₹100.2 Cr | ₹114 Cr | ₹99.4 Cr | ₹121.61 Cr | ₹114.68 Cr | ₹102.43 Cr | ₹107.66 Cr |
| Total Expenses | ₹470.6 Cr | ₹468.3 Cr | ₹367.4 Cr | ₹411.8 Cr | ₹484.6 Cr | ₹427.5 Cr | ₹428.5 Cr | ₹400.4 Cr | ₹467.24 Cr | ₹426.02 Cr | ₹419.01 Cr | ₹379.28 Cr |
| Profit Before Exceptional Items & Tax | ₹55.4 Cr | ₹28.8 Cr | -₹47 Cr | -₹30.4 Cr | ₹68.3 Cr | ₹23.8 Cr | ₹24.8 Cr | ₹6.9 Cr | ₹47.32 Cr | ₹21.61 Cr | ₹16.86 Cr | ₹9.71 Cr |
| Exceptional Items | -₹47.1 Cr | -₹38 Cr | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 |
| Profit Before Tax | ₹8.3 Cr | -₹9.2 Cr | -₹47 Cr | -₹30.4 Cr | ₹68.3 Cr | ₹23.8 Cr | ₹24.8 Cr | ₹6.9 Cr | ₹47.32 Cr | ₹21.61 Cr | ₹16.86 Cr | ₹9.71 Cr |
| Total Tax Expense | -₹6.1 Cr | -₹3.3 Cr | -₹12.1 Cr | -₹8 Cr | ₹18.1 Cr | ₹6.6 Cr | ₹6.5 Cr | ₹1.8 Cr | ₹13.35 Cr | ₹5.47 Cr | ₹4.29 Cr | ₹2.79 Cr |
| Net Profit | ₹14.4 Cr | -₹5.9 Cr | -₹34.9 Cr | -₹22.4 Cr | ₹50.2 Cr | ₹17.2 Cr | ₹18.3 Cr | ₹5.1 Cr | ₹33.97 Cr | ₹16.14 Cr | ₹12.57 Cr | ₹6.92 Cr |
| attributable to Owners | - | - | - | ₹0 | ₹0 | ₹0 | ₹0 | - | ₹0 | ₹0 | ₹0 | ₹0 |
| attributable to NCI | - | - | - | ₹0 | ₹0 | ₹0 | ₹0 | - | ₹0 | ₹0 | ₹0 | ₹0 |
| Other Comprehensive Income | -₹1.6 Cr | ₹0 | -₹40 Lakh | -₹40 Lakh | -₹1 Cr | -₹10 Lakh | -₹20 Lakh | -₹10 Lakh | -₹18 Lakh | -₹14 Lakh | -₹14 Lakh | ₹15 Lakh |
| Total Comprehensive Income | ₹12.8 Cr | -₹5.9 Cr | -₹35.3 Cr | -₹22.8 Cr | ₹49.2 Cr | ₹17.1 Cr | ₹18.1 Cr | ₹5 Cr | ₹33.79 Cr | ₹16 Cr | ₹12.43 Cr | ₹7.07 Cr |
| EBITDA (computed) | ₹112 Cr | ₹85.5 Cr | ₹9.1 Cr | ₹26.1 Cr | ₹123.9 Cr | ₹75.7 Cr | ₹75.3 Cr | ₹58.5 Cr | ₹94.92 Cr | ₹64.82 Cr | ₹58.51 Cr | ₹51.23 Cr |
| Basic EPS | ₹1.17 | ₹-0.48 | ₹0.00 | ₹-1.82 | ₹4.07 | ₹1.39 | ₹1.48 | ₹0.41 | ₹2.76 | ₹1.31 | ₹1.02 | ₹0.56 |
| Diluted EPS | ₹1.17 | ₹-0.48 | ₹0.00 | ₹-1.82 | ₹4.07 | ₹1.39 | ₹1.48 | ₹0.41 | ₹2.76 | ₹1.31 | ₹1.02 | ₹0.56 |
| Segment · Q4 FY26 (latest quarter) | Revenue | Result (PBIT) | Assets | Liabilities |
|---|---|---|---|---|
| Pharmaceuticals | ₹291.6 Cr | ₹34.9 Cr | ₹1,479.6 Cr | ₹281.8 Cr |
| Crop Protection | ₹227.8 Cr | ₹38.9 Cr | ₹830.5 Cr | ₹147.5 Cr |
| Unallocable | ₹0 | ₹0 | ₹55.3 Cr | ₹737.3 Cr |
| Exceptional Item - Employee Benefit Expense | ₹0 | ₹0 | ₹0 | ₹0 |
| Exceptional Item - Impairement Charge | ₹0 | -₹47.1 Cr | ₹0 | ₹0 |
| Segment · FY 2026 (annual) | Revenue | Result (PBIT) | Assets | Liabilities |
|---|---|---|---|---|
| Pharmaceuticals | ₹1,021 Cr | ₹32.8 Cr | - | - |
| Crop Protection | ₹691.6 Cr | ₹51.4 Cr | - | - |
| Unallocable | ₹0 | ₹0 | - | - |
| Exceptional Item - Employee Benefit Expense | ₹0 | -₹38 Cr | - | - |
| Exceptional Item - Impairement Charge | ₹0 | -₹47.1 Cr | - | - |
| Metrics | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Revenue from Operations | ₹1,712.6 Cr | ₹1,859.8 Cr | ₹1,784.6 Cr | ₹2,023.03 Cr | ₹1,720.44 Cr | ₹1,507.26 Cr |
| Other Income | ₹12.3 Cr | ₹5 Cr | ₹2.45 Cr | ₹5.41 Cr | ₹4.98 Cr | ₹3.7 Cr |
| Total Income | ₹1,724.9 Cr | ₹1,864.8 Cr | ₹1,787.05 Cr | ₹2,028.44 Cr | ₹1,725.42 Cr | ₹1,510.96 Cr |
| Cost of Materials Consumed | ₹798.6 Cr | ₹882.6 Cr | ₹805.15 Cr | ₹1,121.59 Cr | ₹906.71 Cr | ₹781.9 Cr |
| Purchases of Stock-in-Trade | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 |
| Changes in Inventories | -₹36.9 Cr | -₹45.3 Cr | ₹19.51 Cr | -₹14.56 Cr | ₹1.67 Cr | -₹5.58 Cr |
| Employee Benefit Expense | ₹266 Cr | ₹242.3 Cr | ₹243.98 Cr | ₹220.4 Cr | ₹164.32 Cr | ₹156.57 Cr |
| Finance Costs | ₹62.1 Cr | ₹75.2 Cr | ₹56.37 Cr | ₹48.1 Cr | ₹36.2 Cr | ₹52.42 Cr |
| Depreciation & Amortisation | ₹163.8 Cr | ₹134.4 Cr | ₹117.61 Cr | ₹109.01 Cr | ₹85.24 Cr | ₹82.46 Cr |
| Other Expenses | ₹464.4 Cr | ₹451.7 Cr | ₹449.02 Cr | ₹438.54 Cr | ₹324.85 Cr | ₹301.22 Cr |
| Total Expenses | ₹1,718 Cr | ₹1,740.9 Cr | ₹1,691.64 Cr | ₹1,923.08 Cr | ₹1,518.99 Cr | ₹1,368.99 Cr |
| Profit Before Exceptional Items & Tax | ₹6.9 Cr | ₹123.9 Cr | ₹95.41 Cr | ₹105.36 Cr | ₹206.43 Cr | ₹141.97 Cr |
| Exceptional Items | -₹85.1 Cr | ₹0 | ₹0 | ₹0 | ₹0 | -₹15.4 Cr |
| Profit Before Tax | -₹78.2 Cr | ₹123.9 Cr | ₹95.41 Cr | ₹105.36 Cr | ₹206.43 Cr | ₹126.57 Cr |
| Total Tax Expense | -₹29.5 Cr | ₹33 Cr | ₹25.9 Cr | ₹26.98 Cr | ₹73.28 Cr | ₹42.14 Cr |
| Net Profit | -₹48.7 Cr | ₹90.9 Cr | ₹69.51 Cr | ₹78.38 Cr | ₹133.15 Cr | ₹84.43 Cr |
| Other Comprehensive Income | -₹2.4 Cr | -₹1.4 Cr | -₹61 Lakh | -₹56 Lakh | -₹1.44 Cr | -₹13 Lakh |
| Total Comprehensive Income | -₹51.1 Cr | ₹89.5 Cr | ₹68.9 Cr | ₹77.82 Cr | ₹131.71 Cr | ₹84.3 Cr |
| EBITDA (computed) | ₹232.8 Cr | ₹333.5 Cr | ₹269.39 Cr | ₹262.47 Cr | ₹327.87 Cr | ₹276.85 Cr |
| Basic EPS | ₹-3.95 | ₹7.37 | ₹5.64 | ₹6.36 | ₹10.80 | ₹6.85 |
| Diluted EPS | ₹-3.95 | ₹7.37 | ₹5.64 | ₹6.36 | ₹10.80 | ₹6.85 |
| Metrics | FY 2026 | FY 2025 | FY 2024 | FY 2023 |
|---|---|---|---|---|
| Total Assets | ₹2,365.4 Cr | ₹2,529.1 Cr | ₹2,487.06 Cr | ₹2,385.46 Cr |
| Non-current Assets | ₹1,481.3 Cr | ₹1,532.2 Cr | ₹1,520.54 Cr | ₹1,446.47 Cr |
| Current Assets | ₹884.1 Cr | ₹996.9 Cr | ₹966.52 Cr | ₹938.99 Cr |
| Property, Plant & Equipment | ₹1,327.1 Cr | ₹1,356.7 Cr | ₹1,060.48 Cr | ₹948.19 Cr |
| Inventories | ₹358.1 Cr | ₹334.5 Cr | ₹303.72 Cr | ₹316.74 Cr |
| Trade Receivables | ₹441.6 Cr | ₹522.4 Cr | ₹550.34 Cr | ₹441.78 Cr |
| Cash & Equivalents | ₹9.6 Cr | ₹12.9 Cr | ₹12.59 Cr | ₹26.71 Cr |
| Equity (Net Worth) | ₹1,199 Cr | ₹1,262.2 Cr | ₹1,187.59 Cr | ₹1,133.47 Cr |
| Equity Share Capital | ₹24.7 Cr | ₹24.7 Cr | ₹24.66 Cr | ₹24.66 Cr |
| Borrowings (Non-current) | ₹373.1 Cr | ₹367.2 Cr | ₹422.85 Cr | ₹489.88 Cr |
| Borrowings (Current) | ₹308 Cr | ₹395.1 Cr | ₹391.89 Cr | ₹258.08 Cr |
| Total Debt (computed) | ₹681.1 Cr | ₹762.3 Cr | ₹814.74 Cr | ₹747.96 Cr |
| Current Liabilities | ₹678.7 Cr | ₹789.8 Cr | ₹756.62 Cr | ₹661.54 Cr |
| Total Liabilities | ₹1,166.4 Cr | ₹1,266.9 Cr | ₹1,299.47 Cr | ₹1,251.99 Cr |
| Metrics | FY 2026 | FY 2025 | FY 2024 | FY 2023 |
|---|---|---|---|---|
| Operating Cash Flow | ₹302.1 Cr | ₹280.4 Cr | ₹186.63 Cr | ₹315.29 Cr |
| Investing Cash Flow | -₹145.3 Cr | -₹136.5 Cr | -₹173.75 Cr | -₹292.33 Cr |
| Financing Cash Flow | -₹160.1 Cr | -₹143.6 Cr | -₹27 Cr | -₹7.69 Cr |
| Capital Expenditure | ₹148.1 Cr | ₹137.3 Cr | ₹204.19 Cr | ₹302.62 Cr |
| Free Cash Flow (computed) | ₹154 Cr | ₹143.1 Cr | -₹17.56 Cr | ₹12.67 Cr |
| Dividends Paid | ₹12.3 Cr | ₹14.8 Cr | ₹14.83 Cr | ₹12.34 Cr |
| Net Change in Cash | -₹3.3 Cr | ₹30 Lakh | -₹14.12 Cr | ₹15.27 Cr |
| Metrics | Q4 FY26 | Q3 FY26 | Q2 FY26 | Q1 FY26 | Q4 FY25 | Q3 FY25 | Q2 FY25 | Q1 FY25 | Q4 FY24 | Q3 FY24 | Q2 FY24 | Q1 FY24 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue from Operations | ₹519.4 Cr | ₹494.3 Cr | ₹318.5 Cr | ₹380.4 Cr | ₹552.4 Cr | ₹447.7 Cr | ₹452.9 Cr | ₹406.8 Cr | ₹514.1 Cr | ₹447.57 Cr | ₹434.88 Cr | ₹388.05 Cr |
| Other Income | ₹6.6 Cr | ₹2.8 Cr | ₹1.9 Cr | ₹1 Cr | ₹50 Lakh | ₹3.6 Cr | ₹40 Lakh | ₹50 Lakh | ₹46 Lakh | ₹6 Lakh | ₹99 Lakh | ₹94 Lakh |
| Total Income | ₹526 Cr | ₹497.1 Cr | ₹320.4 Cr | ₹381.4 Cr | ₹552.9 Cr | ₹451.3 Cr | ₹453.3 Cr | ₹407.3 Cr | ₹514.56 Cr | ₹447.63 Cr | ₹435.87 Cr | ₹388.99 Cr |
| Cost of Materials Consumed | ₹210.3 Cr | ₹187.6 Cr | ₹218.7 Cr | ₹182 Cr | ₹210.7 Cr | ₹212.8 Cr | ₹224.3 Cr | ₹234.8 Cr | ₹183.17 Cr | ₹192.61 Cr | ₹212.3 Cr | ₹217.07 Cr |
| Purchases of Stock-in-Trade | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 |
| Changes in Inventories | ₹6.3 Cr | ₹44.4 Cr | -₹92.4 Cr | ₹4.8 Cr | ₹21.5 Cr | -₹1.9 Cr | -₹22.4 Cr | -₹42.5 Cr | ₹51.08 Cr | ₹14.21 Cr | ₹82 Lakh | -₹46.6 Cr |
| Employee Benefit Expense | ₹66.9 Cr | ₹69.3 Cr | ₹68.1 Cr | ₹61.7 Cr | ₹61.7 Cr | ₹63.2 Cr | ₹61 Cr | ₹56.4 Cr | ₹63.24 Cr | ₹60.74 Cr | ₹60.91 Cr | ₹59.09 Cr |
| Finance Costs | ₹14.6 Cr | ₹15.5 Cr | ₹14.9 Cr | ₹17.1 Cr | ₹17.9 Cr | ₹18.7 Cr | ₹18.8 Cr | ₹19.8 Cr | ₹15.26 Cr | ₹14.24 Cr | ₹13.08 Cr | ₹13.79 Cr |
| Depreciation & Amortisation | ₹42 Cr | ₹41.2 Cr | ₹41.2 Cr | ₹39.4 Cr | ₹37.7 Cr | ₹33.2 Cr | ₹31.7 Cr | ₹31.8 Cr | ₹32.34 Cr | ₹28.97 Cr | ₹28.57 Cr | ₹27.73 Cr |
| Other Expenses | ₹130.3 Cr | ₹110.3 Cr | ₹116.7 Cr | ₹107.1 Cr | ₹135 Cr | ₹101.4 Cr | ₹115.3 Cr | ₹100 Cr | ₹122.26 Cr | ₹115.12 Cr | ₹103.38 Cr | ₹108.26 Cr |
| Total Expenses | ₹470.4 Cr | ₹468.3 Cr | ₹367.2 Cr | ₹412.1 Cr | ₹484.5 Cr | ₹427.4 Cr | ₹428.7 Cr | ₹400.3 Cr | ₹467.35 Cr | ₹425.89 Cr | ₹419.06 Cr | ₹379.34 Cr |
| Profit Before Exceptional Items & Tax | ₹55.6 Cr | ₹28.8 Cr | -₹46.8 Cr | -₹30.7 Cr | ₹68.4 Cr | ₹23.9 Cr | ₹24.6 Cr | ₹7 Cr | ₹47.21 Cr | ₹21.74 Cr | ₹16.81 Cr | ₹9.65 Cr |
| Exceptional Items | -₹47.1 Cr | -₹38 Cr | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 |
| Profit Before Tax | ₹8.5 Cr | -₹9.2 Cr | -₹46.8 Cr | -₹30.7 Cr | ₹68.4 Cr | ₹23.9 Cr | ₹24.6 Cr | ₹7 Cr | ₹47.21 Cr | ₹21.74 Cr | ₹16.81 Cr | ₹9.65 Cr |
| Total Tax Expense | -₹6.1 Cr | -₹3.3 Cr | -₹12.1 Cr | -₹8 Cr | ₹18.1 Cr | ₹6.6 Cr | ₹6.5 Cr | ₹1.8 Cr | ₹13.35 Cr | ₹5.47 Cr | ₹4.29 Cr | ₹2.79 Cr |
| Net Profit | ₹14.6 Cr | -₹5.9 Cr | -₹34.7 Cr | -₹22.7 Cr | ₹50.3 Cr | ₹17.3 Cr | ₹18.1 Cr | ₹5.2 Cr | ₹33.86 Cr | ₹16.27 Cr | ₹12.52 Cr | ₹6.86 Cr |
| Other Comprehensive Income | -₹1.6 Cr | ₹0 | -₹40 Lakh | -₹40 Lakh | -₹1 Cr | -₹10 Lakh | -₹20 Lakh | -₹10 Lakh | -₹18 Lakh | -₹14 Lakh | -₹14 Lakh | ₹15 Lakh |
| Total Comprehensive Income | ₹13 Cr | -₹5.9 Cr | -₹35.1 Cr | -₹23.1 Cr | ₹49.3 Cr | ₹17.2 Cr | ₹17.9 Cr | ₹5.1 Cr | ₹33.68 Cr | ₹16.13 Cr | ₹12.38 Cr | ₹7.01 Cr |
| EBITDA (computed) | ₹112.2 Cr | ₹85.5 Cr | ₹9.3 Cr | ₹25.8 Cr | ₹124 Cr | ₹75.8 Cr | ₹75.1 Cr | ₹58.6 Cr | ₹94.81 Cr | ₹64.95 Cr | ₹58.46 Cr | ₹51.17 Cr |
| Basic EPS | ₹1.18 | ₹-0.48 | ₹0.00 | ₹-1.84 | ₹4.08 | ₹1.40 | ₹1.47 | ₹0.42 | ₹2.75 | ₹1.32 | ₹1.02 | ₹0.56 |
| Diluted EPS | ₹1.18 | ₹-0.48 | ₹0.00 | ₹-1.84 | ₹4.08 | ₹1.40 | ₹1.47 | ₹0.42 | ₹2.75 | ₹1.32 | ₹1.02 | ₹0.56 |
| Segment · Q4 FY26 (latest quarter) | Revenue | Result (PBIT) | Assets | Liabilities |
|---|---|---|---|---|
| Pharmaceuticals | ₹291.6 Cr | ₹34.9 Cr | ₹1,479.6 Cr | ₹281.8 Cr |
| Crop Protection | ₹227.8 Cr | ₹38.9 Cr | ₹830.5 Cr | ₹147.5 Cr |
| Unallocable | ₹0 | ₹0 | ₹55.3 Cr | ₹737.1 Cr |
| Exceptional Item - Employee Benefit expense | ₹0 | ₹0 | ₹0 | ₹0 |
| Exceptional Item - Impairment charge | ₹0 | -₹47.1 Cr | ₹0 | ₹0 |
| Segment · FY 2026 (annual) | Revenue | Result (PBIT) | Assets | Liabilities |
|---|---|---|---|---|
| Pharmaceuticals | ₹1,021 Cr | ₹32.8 Cr | - | - |
| Crop Protection | ₹691.6 Cr | ₹51.4 Cr | - | - |
| Unallocable | ₹0 | ₹0 | - | - |
| Exceptional Item - Employee Benefit expense | ₹0 | -₹38 Cr | - | - |
| Exceptional Item - Impairment charge | ₹0 | -₹47.1 Cr | - | - |
Board & Governance of Hikal Pharmaceuticals Limited
As per the corporate governance filing with NSE for the quarter ended 31-MAR-2026, the board of Hikal Pharmaceuticals Limited has 10 directors - 5 independent and 3 executive. The board is chaired by Jai Hiremath.
| Director | Position | On board since | Listed boards |
|---|---|---|---|
| Jai Hiremath | Executive Director · Chairperson | 1991-02-22 | 1 |
| Shivani Bhasin Sachdeva | Non-Executive - Independent Director | 2019-08-01 | 1 |
| Shrikrishna Kiran Adivarekar | Non-Executive - Independent Director | 2021-12-22 | 4 |
| Ramachandra Kaundinya Vinnakota | Non-Executive - Independent Director | 2023-10-01 | 1 |
| Ravi Brijmohan Kapoor | Non-Executive - Independent Director | 2024-01-11 | 2 |
| Ranjana Shivanand Salgaocar | Non-Executive - Independent Director | 2024-03-23 | 1 |
| Sugandha Hiremath | Non-Executive - Non Independent Director | 1992-02-05 | 1 |
| Amit Kalyani | Non-Executive - Non Independent Director | 2012-02-09 | 6 |
| Sameer Hiremath | Executive Director · MD | 1999-05-26 | 1 |
| Sarangan Suresh | Executive Director | 2024-04-01 | 1 |
| Committee | Members |
|---|---|
| Audit Committee | Ramachandra Kaundinya Vinnakota (Chairperson), Ravi Brijmohan Kapoor, Ranjana Shivanand Salgaocar, Sugandha Hiremath |
| Nomination and remuneration committee | Ramachandra Kaundinya Vinnakota (Chairperson), Shivani Bhasin Sachdeva, Ravi Brijmohan Kapoor, Shrikrishna Kiran Adivarekar, Jai Hiremath |
| Stakeholders Relationship Committee | Ravi Brijmohan Kapoor (Chairperson), Ranjana Shivanand Salgaocar, Sugandha Hiremath |
| Risk Management Committee | Jai Hiremath (Chairperson), Ramachandra Kaundinya Vinnakota, Ravi Brijmohan Kapoor, Sameer Hiremath, Anish Swadi |
| Corporate Social Responsibility Committee | Jai Hiremath (Chairperson), Ranjana Shivanand Salgaocar, Sugandha Hiremath, Sameer Hiremath |
Charges & Borrowings Hikal Pharmaceuticals Limited
Hikal Pharmaceuticals Limited does not have any charges (loans) registered with the Registrar of Companies.
Employees and EPFO Compliance at Hikal Pharmaceuticals Limited
View historical data on people associated with Hikal Pharmaceuticals Limited, including employment history and EPFO contributions.
Employee Count & EPFO Data of Hikal Pharmaceuticals Limited
Access employee headcount trends, monthly PF payment records, EPFO establishment details, and compliance data.
GST Compliance of Hikal Pharmaceuticals Limited
GSTIN & GST Filing Data of Hikal Pharmaceuticals Limited
Access GSTIN registrations, state-wise filing compliance, HSN/SAC codes, and detailed goods & services data.
Credit Ratings, Litigation & Regulatory Alerts for Hikal Pharmaceuticals Limited
Credit Ratings, Legal Cases & Regulatory Alerts of Hikal Pharmaceuticals Limited
Access complete credit rating history, litigation records, regulatory alerts, and compliance data.
MSME Payment Delays by Hikal Pharmaceuticals Limited
MSME Payment Delays by Hikal Pharmaceuticals Limited
Track payments outstanding to micro and small enterprise vendors, as disclosed in half-yearly MSME-1 returns filed with the MCA.
Subsidiaries & Group Companies of Hikal Pharmaceuticals Limited
Subsidiaries & Group Companies of Hikal Pharmaceuticals Limited
See the full corporate group - holding company, subsidiaries, associates and joint ventures of Hikal Pharmaceuticals Limited with ownership details.
MCA Filings & Documents of Hikal Pharmaceuticals Limited
MCA Filings & Documents of Hikal Pharmaceuticals Limited
Download official documents filed with the Ministry of Corporate Affairs - from incorporation papers to the latest annual filings.
Recent Activity on Hikal Pharmaceuticals Limited
Recent News on Hikal Pharmaceuticals Limited
Frequently Asked Questions about Hikal Pharmaceuticals Limited
Hikal Pharmaceuticals Limited has been "Amalgamated" (merged) as per MCA records. The company was combined with another entity and no longer exists as a separate legal entity. Business activities, if any, continue under the successor entity.
Hikal Pharmaceuticals Limited is a amalgamated private limited company in the metal and minerals sector based in Navi Mumbai, Maharashtra, India. It was incorporated on 23 September 1985 and is registered under CIN U26921MH1985PTC171427. The company was amalgamated as per MCA records and no longer exists as a legal entity.
Hikal Pharmaceuticals Limited was incorporated on 23 September 1985. Registered with ROC Mumbai.
The current directors of Hikal Pharmaceuticals Limited are:
The CIN (Corporate Identification Number) of Hikal Pharmaceuticals Limited is U26921MH1985PTC171427. It is issued by the Ministry of Corporate Affairs under the Companies Act, 2013, and uniquely identifies the company in India.
The primary industry of Hikal Pharmaceuticals Limited is metal and minerals. The company specifically operates in mineral products.